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Objective: We aim to analyze changes in incidence, comorbidity profile, length of hospital stay
(LOHS), costs and in-hospital mortality (IHM) of patients hospitalized for acute exacerbations
of chronic obstructive pulmonary disease (AE-COPD) over a 5-year study period in Spain.
Methods: We selected all hospital admissions for AE-COPD between 2006 and 2010 from the
National Hospital Discharge Database covering the entire population of Spain.
Results: We identified a total of 215,835 patients. Overall crude incidence had decreased from
2.9 to 2.4 exacerbations of COPD per 10.000 inhabitants from 2006 to 2010 (p < 0.001). In 2006,
17.9% of patients had a Charlson Index >2 and in 2010, the prevalence had increased to 25.0%
(p < 0.001). Regarding to treatment, we detected a significant increase in the use of non-
invasive ventilation from 2.1% in 2006 to 5.3% in 2010 (p < 0.001). The median LOHS was 7 days
in 2006 and it remained stable until 2010. During the period studied, the mean cost per patient
increased from 3747 to 4129 Euros. Multivariate analysis showed that incidence of hospitaliza-
tions for AE-COPD and IHM had significantly decreased from 2006 to 2010.
Conclusions: The current study provides data indicating a decrease in incidence of hospital ad-
missions for AE-COPD in Spain from 2006 to 2010 with concomitant reduction in IHM, despite
increasing comorbidity during this period, with no variations in LOHS. The mean cost per pa-
tient has risen significantly.
ª 2013 Elsevier Ltd. All rights reserved.lud.madrid.org (J. de Miguel-Dı´ez).
3 Elsevier Ltd. All rights reserved.
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718Background
9th revision (ICD-9CM). This information is collected by theChronic obstructive pulmonary disease (COPD) is a leading
cause of morbidity and mortality worldwide and it remains
a major public health problem. The prevalence of COPD is
about 10%1 and it is expected to increase rapidly in the near
future due to the persistence of risk factors of COPD
and changes in the age characteristics of the world popu-
lation.2 Actually, COPD is the fourth leading cause of death
in the United States and is projected to become the third
leading cause of death by 2020.3 A large proportion of
morbidity and mortality from COPD results from acute
exacerbations.4
Acute exacerbation of COPD (AE-COPD) is defined as
a sustained worsening of the patient’s condition, from the
stable state and beyond normal day-to-day variations, that
is acute in onset and requires a change in regular medi-
cation in a patient with underlying COPD.5 Exacerbations
are major events in the disease course, especially when the
patient needs hospitalization. Indeed, AE-COPD is asso-
ciated with a decline in lung function, impaired health-
related quality of life, and increased mortality and ele-
vated costs.6,7 Hospitalizations for AE-COPD account for
a large proportion of COPD-related hospital healthcare
expenditure. The number and duration of hospitalization,
severity of airway obstruction, smoking, mechanical ven-
tilation, admission to the ICU, and comorbidities affect the
cost of COPD significantly.8 Therefore, to improve out-
comes and reduce mortality due to COPD, we need to
optimize the management of acute exacerbations.
Collecting data about hospitalizations for AE-COPD is
important at a country level to evaluate the incidence,
patient characteristics and outcome of the hospital ad-
missions in variables such as length of stay (LOHS), com-
plications, mortality and burden of disease. For example,
data obtained from the French national hospital discharge
database, showed that hospitalizations rates for AE-COPD
have increased between 1998 and 2007, especially among
women.9 The US National Hospital Discharge Survey has also
reported that the hospitalizations rates for COPD increased
over the lasts decades, and the gap between men and
women disappeared.10 Comparisons of hospital admissions
for AE-COPD and outcomes between countries could pro-
vide information that would help to understand the possible
differences and would also aid for planning the provision of
healthcare services. The discharge database provides
a large alternative information source to describe and
analyze the trends and characteristics of hospitalizations
for AE-COPD at a national level.
The aim of this study was to analyze national repre-
sentative hospital discharge data, collected from 2006 to
2010 years, to elucidate changes in the incidence, comor-
bidity profiles, length of hospital stay (LOHS), costs and in-
hospital mortality (IHM) of patients hospitalized for AE-
COPD in Spain over a 5-year study period.
Methods
According to the Spanish Health System Organization, each
physician must declare, at the time of discharge of each
hospitalization all diagnoses and procedures performed,using the code of the International Classification of Disease,
Spanish National Hospital Database, namely “Conjunto
Minimo Basico de Datos” (CMBD) that compiles all the
public and private hospital data covering over 95% of hos-
pital discharges.11 The CMBD database includes patients’
variables (sex, date of birth), date of admittance, date of
discharge, discharge destination (home, decease or other
health/social institution), up to 14 discharge diagnosis and
up to 20 procedures performed during the admission.
We selected all patients hospitalized for AE-COPD
(ICD-9-CM procedure code 491.21) during 2006e2010
year period. We calculated the yearly age- and sex-
specific incidence rates by dividing the number of cases per
year per sex and age group, with the corresponding number
of person in that population group according to the National
Institute of Statistics (INE) reported at December 31 of each
year.12 The incidence rates were expressed in terms of
10,000 inhabitants. The proportion of patients that died
during the hospital admission (in-hospital mortality), LOHS,
and costs were also estimated for each year studied. Costs
were calculated using Diagnosis-Related Groups (DRG) for
the disease. DRG represents a medical-economic entity
concerning a set of diseases requiring analogous
management resources.13 All costs shown are adjusted for
the increment of the inflation in the same period in Spain.
We analyzed the use of ventilatory support during AE-
COPD hospitalization. Use of non-invasive positive pressure
ventilation (NIPPV) and invasive mechanical ventilation
(IMV) was determined based on procedure codes 93.90 and
96.04, respectively. If both procedures were used the pa-
tient was included in the IMV group. Clinical characteristics
included information in overall comorbidity at the time of
the hospitalization, which was assessed by computing the
Charlson comorbidity index. We calculated the Charlson
comorbidity index (CCI) based on coded data available in
the discharge register using the codes and methods
described by Deyo et al.14 The index applies to 19 disease
categories that are summated to obtain an overall score for
each patient. We divided patients into 3 categories: low
index, which corresponds to patients with no previously
recorded disease categories in the Charlson comorbidity
index; medium index, patients with one or two disease
categories; and high index, patients with more than two
disease categories. The validity of information on comor-
bidity derived from ICD-9 administrative data has been
assessed comparing this information with that recoded in
the patient medical history, finding that administrative
data generally agree with patient chart data for recording
of comorbidities although comorbidities tend to be under-
reported in administrative data.15 The Charlson comorbid-
ity index is very frequently used in epidemiological inves-
tigation to reduce potential confounding. However,
residual confounding by comorbidity is inevitable; given
how these score is derived.16Statistical analysis
Quantitative variables are expressed as means, medians,
range and inter-quartile range (IQR). Qualitative variables
are expressed as frequencies and percentages.
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exact test, Student’s t-test, Wilcoxon rank-sum test,
ANOVA or KruskaleWallis test as appropriate. The multi-
variate analysis of time trend of study variables were con-
ducted using Poisson and logistic regression models and
adjusting by age, sex and other co-variables when appro-
priate. We then checked for interactions between the in-
dependent variables in the regression models. Estimations
were made using STATA version 10.1 program (StataCorp LP,
Lakeway DriveCollege Station, Texas, USA) and statistical
significance was set at two-tailed a < 0.05.
Data were treated with full confidentiality, according to
the Spanish legislation. Patient identifiers were deleted
before the database was provided to the authors in order to
keep strict patient confidentiality. It is not possible to
identify patients at individual levels either in this paper or in
the database. Given the anonymous and mandatory nature
of the data informed consent was not required or necessary.
The Spanish Ministry of Health evaluated the protocol of our
investigation and considered that it met all ethical aspects
according to the Spanish legislation so provided us the
anonymous database. For all the previous reasons the
requirement for ethical approval was not necessary.
Results
We identified a total of 215,835 discharges of patients
(186,239 men and 29,596 women) having hospital admis-
sions from AE-COPD from 2006 to 2010. Table 1 reflects the
incidence rates and IHM among patients hospitalized with
AE-COPD in Spain from 2006 to 2010 according to sex. The
overall crude incidence has decreased from 2.9 to 2.4
hospitalizations for AE-COPD hospitalizations per 10,000
inhabitants from 2006 to 2010 in Spain (p < 0.001), the
reduction is significant in both men and women. The mean
IHM for the entire period increased by age as follows: 1.4%,
2.4%, 3.6%, 5.7% and 9.2% for the age groups 40e54, 55e64,
65e74, 75e84 and 85 years respectively (test for trend:
p < 0.001).
We observed a seasonal predominance in the distribu-
tion of hospital admissions over time. Thus, the incidence
rate was higher during the winter months with a very sim-
ilar curve for all years studied (Fig. 1).Table 1 Incidence rates and in-hospital mortality (IHM) amon
obstructive pulmonary disease (AE-COPD) in Spain from 2006 to 2
Sex 2006
N Z 44.383
20
N
Incidence rates per 10,000 inhabitants Men 38.7 39
Women 5.5 5.
Both 2.9 3.
IHM% (SE) Men 5.1 (0.1) 5.
Women 5.4 (0.2) 6.
Both 5.2 (0.1) 5.
Incidence rates calculated by dividing the number of cases per year se
group according to the National Institute of Statistics (INE) reported
IHM: In-hospital mortality calculated dividing the number of death by
SE: Standard error.
a p Value for time trend estimated using Poisson regression modelsRegarding to treatment, we observed changes in the use
of ventilatory support during AE-COPD from 2006 to 2010. In
this sense, we detected a significant increase in the use of
non-invasive ventilation. In parallel, the use of mechanical
ventilation was significantly reduced over time (Table 2).
Themedian LOHS for hospital admissions for AE-COPDwas
7 days (25/75 percentiles; 4 and 22 respectively) in 2006, and
it remained stable until 2010. Time trends in Charlson co-
morbidity index and the prevalence of discharge destinations
are summarized in the Table 3. With regard to comorbidity,
in 2006, 55.4% of patients had a Charlson Index of 0, 26.6% of
1e2, and 17.9% >2. In 2010, the proportion of patients who
had been hospitalized for AE-COPD and had Charlson Index of
1e2 or >2 had increased to 26.8% and 25.0% respectively
(p< 0.001). On the other hand, the proportion of individuals
who were discharged to a social or health institution rose
significantly from 2.0% in 2006 to 2.9% in 2010.
The total hospital costs for hospital admissions for AE-
COPD in Spain were 167.92 million of Euros in 2010 very
similar to the total cost five years before (166.27 millions).
During the period studied, the mean cost per patient
increased from 3747 Euros in 2006 to 4129 Euros in 2010
(Table 4).
Table 5 summarizes the results of the multivariate anal-
ysis. No interactions between independent variables proved
statistically significant. After controlling for possible con-
founders using Poisson regression models, we observed that
the incidence of hospitalizations for AE-COPD has sig-
nificantly decreased from 2006 to 2010 for men and women,
although the risk of hospitalization is lower in women than in
men. With regard to IHM, after adjusting the logistic
regression model, there was a significant decrease from
2006 to 2010. For both sexes the risk of in hospital death was
higher as age and Charlson comorbidity index increased.
Discussion
In this observational study, we found a significant decrease
in the incidence rates of hospitalizations from 2006 to 2010.
This decrease could be justified, in part, by a reduction in
the prevalence of the disease. In this sense, Soriano et al.17
report a substantial reduction of 50.4% in the prevalence of
COPD in Spain from 1997 to 2007 in subjects aged 40e69g patients hospitalized with acute exacerbations of chronic
010 according to sex.
07
Z 45.735
2008
N Z 42.909
2009
N Z 42.143
2010
N Z 40.665
pa Value
.3 35.8 34.5 32.4 <0.001
3 5.1 4.8 4.7 <0.001
0 2.6 2.7 2.4 <0.001
3 (0.1) 5.1 (0.1) 4.9 (0.1) 4.5 (0.1) <0.001
0 (0.3) 5.6 (0.3) 4.3 (0.2) 4.8 (0.2) 0.005
42 (0.1) 5.1 (0.1) 4.8 (0.1) 4.5 (0.1) <0.001
x age with the corresponding number of person in that population
at December 31 each year.12
the number of hospitalized subjects in that sex.
for incidence rate and logistic regression for IHM.
Figure 1 Temporal distributions of hospital admissions for
acute exacerbations of chronic obstructive pulmonary disease
(AE-COPD) per 10,000 inhabitants in Spain from 2006 to 2010.
720years (from 9.1% to 4.5%), with also an unexpected shift to
a milder severity in the population distribution. These
findings remain unexplained and may be caused by changes
in smoking habits and in the management of COPD. The
prevalence of smokers in adults in Spain significantly
dropped in males from 39.9% in 1999 to 32.1% in 2007, while
only from 24.6% to 22.1% in females in the same period.12
Moreover, undertreatment (but not underdiagnosis) was
significantly reduced during the same period (from 81% in
1997 to 54% in 2007).17
As there are no similar studies in Spain, it is necessary to
make comparisons with other countries. Fuhrrman et al.9
examined temporal trends in AE-COPD related hospital
admissions in France between 1998 and 2007, and detected
than admissions rates for AE-COPD increased significantly,
especially among women, while overall admissions rates for
medical condition slightly decreased. On the other hand,
Antunes et al.18 did not detect changes in hospitalization
rates for COPD in Brazil during the period 1998e2009. The
present results agree with the studies conducted in other
countries, where have been observed a trend to decrease
the incidence rates for COPD hospitalizations during the
period under review. So, Kinnula et al.19 assessed the effect
of a program for COPD in Finland from 1998 to 2007, and
noted a reduction in the rate of hospitalizations associated
with this disease. On the other hand, Wilson et al.20
examined trends in hospital admissions and mortality
from COPD in Australia between 1993 and 2003 and found
that the admission rates were declining for men, but thereTable 2 Use of non-invasive positive pressure ventilation (NIPP
erbations of COPD (AE-COPD) in Spain from 2006 to 2010.
Non-invasive positive pressure ventilation
No Yes
N % N
Year 2006 43,451 97.9 932
2007 44,703 97.7 1032
2008 41,694 97.2 1215
2009 40,730 96.6 1413
2010 38,506 94.7 2159
The time trend are statistically significant in both cases (p < 0.001),was no indication than admissions rates for women had
reached a peak. In our study, which analyzes a more recent
time period, we have seen a decrease in the incidence rates
of hospitalization for COPD in both sexes regardless of age
group analyzed.
The existence of seasonality in hospitalizations for AE-
COPD observed in our study, being more frequent during
the winter months, confirms the trends shown in previous
studies. Fuhrrman et al.9 found a strong seasonal pattern of
admission for AE-COPD, matching that of general practi-
cioners visits for influenza-like illness. Viral infections have
been found in more than 40% of patients with AE-COPD and
viral respiratory tract infection in an important trigger of
severe AE-COPD.21,22 In fact, in our study we found a coin-
cident pattern between the peaks of hospital admissions for
COPD and influenza epidemics reported the Spanish
Surveillance.23
With regard to comorbidity associated, in our study we
observed an increasing trend among patients admitted for
AE-COPD. However, we have not detected a significant
worsening in LOHS. The increase of discharges to health/
social institutions detected in this study could account for
these results. We belief possible explanations could
include: greater prevalence of risk factors and comorbid-
ities in AE-COPD patients, increasing availability for these
institutions, and changes in practices that may have led
hospitals to discharge these patient to long term facilities
in a greater proportion. In a recent study which evaluated
trends in first-time hospitalizations with chronic obstructive
pulmonary disease (COPD) during the period from 2002 to
2008, was also observed a decrease in the total rate of
COPD hospitalizations associated with increased
comorbidity.24
Regarding the cost in this study we have observed, as in
others,25 an increase of the mean cost per patient during
the study time. Increased comorbidity is one of the factors
that may have influenced in this trend. In any case, because
of hospitalizations for AE-COPD are responsible for most of
the expense related to the disease8 reducing the frequency
of severe exacerbations may help to control COPD-related
costs.
For IHM, we have shown a declining mortality rates for
AE-COPD from 5.1% to 4.5% over 2006e2010, both men and
women. The mean IHM for the entire period increased with
increasing age. This mortality rate is lower than that
obtained in other studies based on hospital dischargeV) and invasive mechanical ventilation (IMV) for acute exac-
Invasive mechanical ventilation
No Yes
% N % N %
2.1 44,039 99.2 344 0.8
2.3 45,366 99.2 369 0.8
2.8 42,610 99.3 299 0.7
3.4 41,879 99.4 264 0.6
5.3 40,429 99.4 236 0.6
the increased use of NIPPV and the decreased use of IMV.
Table 3 Length of stay (LOHS), Charlson comorbidity index and discharge destinations of patients hospitalized for acute
exacerbations of chronic obstructive pulmonary disease (AE-COPD) in Spain from 2006 to 2010.
2006 2007 2008 2009 2010 pa
Discharge destinationsa Home (%) 98.0 97.7 97.2 97.4 97.0 <0.001
Health/social
institution (%)
2.0 2.2 2.7 2.6 2.9
Charlson comorbidity index 0 (%) 55.4 54.9 51.9 50.1 48.1 <0.001
1e2 (%) 26.6 27.1 26.0 26.3 26.8
>2 (%) 17.9 17.9 22.0 23.4 25.0
LOHS Median (IQR) 7 (4e22) 7 (4e22) 7 (4e22) 7 (4e21) 7 (4e20) 0.567
IQR: Inter-quartile ranges.
a p Value for time trend estimated using logistic regression adjusted by age and sex.
Hospital admissions for exacerbation of COPD 721database in other countries, that have shown in-hospital
lethality around 6e8%.9,26 Furthermore, O’Farrell et al.27
observed than, although death increased between 2000
and 2009 for both sexes, reduction in deaths was sig-
nificantly higher among men. Wilson et al.20 also showed
a declining mortality rates for COPD in Australia between
1993 and 2003, in contrast with increasing COPD hospitali-
zations and mortality in women. On the other hand,
a recent study in Spain has also shown a downward trend in
COPD mortality rates for both sexes.28 An increase in the
average age at death for men and women with COPD was
also observed. Moreover, in our study we observed, con-
sistent with previous studies,29 that the risk of death
increased with age and number of comorbid conditions.
IHM fell during the study period while comorbidity
increased, suggesting better vital outcome of sever AE-
COPD. Improved patient management, including the wide-
spread use of non-invasive ventilation (NIV) in the most
severe COPD, probably explains these trends. In this way,
George et al.,30 in a UK national audit performed in 2008 to
survey the organization and delivery of clinical care pro-
vided to patients admitted to hospital with COPD, in addi-
tion to checking a decrease in hospital mortality compared
with the 2003 UK audit, noted that more patients were
discharged treated with NIV if acidotic. In our study we
have also seen an increasing trend in the use of NIV, along
with a decrease in the use of invasive mechanical ven-
tilation (IMV). In the same way, Chandra et al.31 also
examined patterns and outcome of NIV treatment for acute
exacerbations in United States during 1998e2008, andTable 4 Costs for hospital admissions from acute exacerbations
from 2006 to 2010.
Year Mean (V) Median (V) Percentile 25
2006 3746.6 4491.6 2347.3
2007 3892.0 4680.2 2445.9
2008 4080.3 4922.3 2639.6
2009 4115.7 4961.7 2660.7
2010 4129.4 4891.3 2711.4
All costs shown are adjusted for the increment of the inflation in the
a p Value for comparing means along the study period.found than a more than 4-fold increase in NIV occurred
during these years, whereas the need for intubation, the
use of IMV and in-hospital mortality declined. In another
recent study that evaluated the prevalence and prognosis
of COPD in critically ill patients between 1998 and 2008 it
was also found that, during the course of the 11 years, the
use of NIV within the COPD cohort more than doubled.32
Simultaneously, the risk-adjusted mortality of patients
with COPD improved. A variety of factors may have con-
tributed to explain these trends. Furthermore many studies
have demonstrated the efficacy of NIV to reduce the need
for invasive mechanical ventilation and in-hospital mortal-
ity, so that the indications have been increasing over
time.33e35
We should recognize strength and limitations of the
current study. The main strength lies in a large sample size
and standardized methodology maintained constant along
the study period. Nevertheless, our study presents some
limitations. Firstly, a potential source of bias comes from
use of ICD-9-CM diagnosis codes for identifying patients
hospitalized for COPD exacerbations. In this sense, it is
possible that the coding practice may have improved along
the study period36 and therefore may have some influence
on our results. In any case we believe that this effect, if
exists, would be of small magnitude and not affect the main
conclusion of our investigation for the following reasons: (1)
the short period covered, only 5 years; (2) the use of one
single code to identify AE-COPD; (3) we only considered an
AE-COPD case if the ICD-9-CM code 491.21 appeared as the
primary diagnosis; (4) along the study period no changes inof chronic obstructive pulmonary disease (AE-COPD) in Spain
Percentile 75 Total cost
(Millions of V)
pa
4491.6 166.2 <0.001
4680.2 178.0
4922.3 175.0
4961.7 173.4
4891.3 167.9
same period in Spain.
Table 5 Multivariate analysis of trends and factors associated with incidence and in-hospital mortality among patients hos-
pitalized with acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) in Spain from 2006 to 2010, according to
sex.
Incidence of hospitalizations for AE-COPD In-hospital mortality after hospitalizations
for (AE-COPD
Risk rate ratios (95% confidence intervals)a Odds ratios (95% confidence intervals)b
Age 40e54 e e
55e64 5.7 (5.5e5.8) 1.6 (1.3e2.0)
65e74 18.5 (18.1e19.0) 2.3 (1.9e2.8)
75e84 40.1 (39.3e41.0) 3.6 (3.0e4.3)
85 51.3 (50.1e52.5) 5.7 (4.7e6.8)
Sex Men
Women 0.1 (0.1e0.1) 0.9 (0.9e1.0)
Charlson
comorbidity
index
0
1e2 0.5 (0.5e0.5) 1.2 (1.2e1.3)
>2 0.4 (0.3e0.4) 1.9 (1.8e2.0)
Year 2006
2007 1.0 (0.9e1.0) 1.0 (0.9e1.0)
2008 0.9 (0.9e0.9) 0.9 (0.8e1.0)
2009 0.8 (0.8e0.8) 0.8 (0.8e0.9)
2010 0.8 (0.8e0.8) 0.8 (0.7e0.8)
a Calculated using multivariate Poisson regression. Dependent variable “Incidence of hospitalizations”.
b Calculate using logistic regression. Dependent variable “In hospital mortality after hospitalizations”.
The independent variables included in the models are those shown in the table.
722the recommendations for the codification method for acute
exacerbation of COPD have been done in Spain. In any case,
despite the limitations of the use of ICD-9-CM, Stein et al.37
have shown that the use of a single primary code specially
for AE-COPD (ICD-9-CM 491.21) offers the highest positive
predictive value (97%) for identifying hospitalizations for
AE-COPD compared to the use of multicode algorithms. In
our study we have used this code, as in other similar
studies.38
Another limitation of this study is that outcomes were
limited to the variables coded which do not include rele-
vant data such as the severity of the exacerbations, phar-
macologic treatments, or response to NIV treatment,
among others. Finally, the study period (5 years) may be
short to identify changes in the time trends so future
investigation could consider using a longer period.
In conclusion, the current study provides clear and valid
data indicating a decrease in incidence of hospital admis-
sions for AE-COPD in Spain from 2006 to 2010 with con-
comitant reduction in-hospital mortality, despite increasing
comorbidity during this period, with no variations in LOHS.
The mean cost per patient has risen significantly. These re-
sults indicate that probably, the management of the patient
undergoing an exacerbation of COPD has improved in Spain
during the study period while the health profile of hospital-
ized patients has worsen. In any case, this time trend points
to a decrease in the burden of COPD for hospitalizations in
Spain, and may be useful for planning future resources.Acknowledgments
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